Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Medical Devices

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

International Business Times UK

Here’s What to Expect From Abbott Laboratories’ Next Earnings Report

Abbott Laboratories is expected to announce its first-quarter results this month, and analysts predict a single-digit growth in the company’s bottom-line figure.

Barchart

What Are Wall Street Analysts' Target Price for Abbott Laboratories Stock?

Despite Abbott Laboratories’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Medical Device Stocks to Buy for Consistent Growth

The medical devices industry is on the verge of an incoming boom, fueled by its growing demand and technological advancements. In this evolving landscape, investors could scoop up shares of robust medical device stocks Alcon (ALC), Becton, Dickinson (BDX), and Abbott (ABT) for solid gains. Read more….

StockNews.com

3 MedTech Stocks Innovating Healthcare

MedTech’s bright future is fueled by rapid tech advancements and increasing demand for medical devices, implants, and precision treatments, driven by an aging population and rising global disease rates. Given this backdrop, adding strong MedTech stocks like Boston Scientific (BSX), Stryker (SYK), and Abbott (ABT) to one’s portfolio could be…

StockNews.com

How Is Abbott's Stock Performance Compared to Other Medical Devices Stocks?

Despite Abbott’s recent underperformance over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

Barchart

3 Stocks That Could Deliver Healthy Returns This Year

The stock market will likely stay under pressure this year, with stubborn inflation and elevated interest rates. However, the Fed’s decision could largely be influenced by concerns about the recent banking crisis. Amid such uncertainty, fundamentally sound stocks Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Humana (HUM) could be…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

This Top-Rated Healthcare Stock Is Trading at a 25% Discount

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

StockNews.com

5 Ultra-Safe Dividend Aristocrats to Buy in a Market Downturn

Worries over intensifying supply disruptions with growing sanctions on Russia have shaken investors. Furthermore, rising crude oil prices coupled with record-high inflation have given rise to recession fears. Thus, we think it could be wise to bet on ultra-safe dividend aristocrats Johnson & Johnson (JNJ), Walmart (WMT), PepsiCo (PEP), Abbott…

StockNews.com

Johnson & Johnson Suspends Sales Forecast For COVID-19 Vaccine, Trims FY22 Profit Outlook

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

Benzinga

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Robert Ford

58 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.